Company Description
Rejection hurts, but organ transplant rejection hurts worse, and XDx wants to help. The company develops tests that monitor for cellular rejection...
Key XDx Financials
| Company Type | Private - NASDAQ (GM): XDXI Proposed Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2006 Sales (mil.) | $2.9 |
| 2006 Employees | 107 |
More XDx Financials (4 pages)
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about XDx's competition across multiple industries
Top XDx Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
XDx Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| VP, Corporate Development | Dirk Lammerts | Network | E-mail |
| President, CEO, and Director | Pierre Cassigneul | Network | E-mail |
| CFO | Jay M. Moyes | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.